Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in Asthmatics
The purpose of this study is to compare the test product Budesonide/formoterol Easyhaler with
 the marketed product Symbicort Turbohaler in terms of the drug absorbed into the bloodstream.
Inclusion Criteria:

 -  Males or females aged 18-60 years with documented diagnosis of asthma

 -  Prebronchodilator forced expiratory volume in one second (FEV1) at least 80% of the
 predicted value

 -  The asthma should be stable on the same regular treatment for at least 4 weeks before
 screening.

 Exclusion Criteria:

 -  Use of oral, parenteral or rectal corticosteroids within 4 weeks preceding the
 screening

 -  Respiratory infection within 4 weeks preceding the screening

 -  Any condition requiring regular concomitant treatment or likely to need concomitant
 treatment during the study with medicinal products which have pharmacokinetic
 interactions with budesonide

 -  Any disorder or clinically significant abnormal laboratory value or physical finding
 that may interfere with the interpretation of test results or cause a health risk for
 the subject if he/she participates in the study